Excellence in treatment of chronic kidney disease with SGLT-2 inhibitors

Sciarc GmbH supported by an educational grant from Boehringer Ingelheim & Eli Lilly and Company |
Thursday

Chair: Per-Henrik Groop (FIN)

18:30 – 18:35Welcome & IntroductionPer-Henrik Groop (FIN)
18:35 – 18:45Removing barriers to the treatment of CKDJennifer Green (USA)
18:45 – 18:55New paths to improve clinical results in CKD with SGLT2- inhibitorsPeter Rossing (DNK)
18:55 – 19:00Discussion & ClosurePer-Henrik Groop (FIN)

supported by an educational grant from